The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Aug. 09, 2022

Filed:

Jun. 15, 2021
Applicant:

Alnylam Pharmaceuticals, Inc., Cambridge, MA (US);

Inventors:

Kevin Fitzgerald, Brookline, MA (US);

William Querbes, Boston, MA (US);

James Butler, Lynnfield, MA (US);

Stephanie Williams, Littleton, MA (US);

Abigail Liebow, Somerville, MA (US);

Gregory Hinkle, Plymouth, MA (US);

Martin A. Maier, Belmont, MA (US);

Stuart Milstein, Arlington, MA (US);

Satyanarayana Kuchimanchi, Acton, MA (US);

Muthiah Manoharan, Weston, MA (US);

Assignee:

Alnylam Pharmaceuticals, Inc., Cambridge, MA (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
C12N 15/113 (2010.01); A61K 31/713 (2006.01); A61P 3/04 (2006.01); A61P 43/00 (2006.01); A61P 13/12 (2006.01); A61P 1/18 (2006.01); A61P 3/10 (2006.01); A61P 9/12 (2006.01); A61P 15/08 (2006.01); A61P 9/10 (2006.01); A61P 1/16 (2006.01); A61P 3/06 (2006.01);
U.S. Cl.
CPC ...
C12N 15/113 (2013.01); A61K 31/713 (2013.01); A61P 1/16 (2018.01); A61P 1/18 (2018.01); A61P 3/04 (2018.01); A61P 3/06 (2018.01); A61P 3/10 (2018.01); A61P 9/10 (2018.01); A61P 9/12 (2018.01); A61P 13/12 (2018.01); A61P 15/08 (2018.01); A61P 43/00 (2018.01); C12N 2310/14 (2013.01); C12N 2310/315 (2013.01); C12N 2310/321 (2013.01); C12N 2310/322 (2013.01); C12N 2310/335 (2013.01); C12N 2310/343 (2013.01); C12N 2310/3515 (2013.01);
Abstract

The present invention relates to RNAi agents, e.g., double-stranded RNAi agents, targeting the apolipoprotein C3 (APOC3) gene, and methods of using such RNAi agents to inhibit expression of APOC3 and methods of treating subjects having an APOC3 associated disorder, e.g., hypertriglyceridemia.


Find Patent Forward Citations

Loading…